Roche CHF Test Will Benefit From Reimbursement Advantages In 2003
This article was originally published in The Gray Sheet
Executive Summary
Roche Diagnostics' newly approved NT-proBNP test for congestive heart failure will enjoy a substantially higher reimbursement rate beginning in January
You may also be interested in...
Beckman Agreement Will Give Biosite Automated Platform For BNP Assay
Biosite will leverage Beckman Coulter's U.S. installed base of automated immunoassay analyzers to grow its market share in BNP testing under a long-term development deal between the firms
Beckman Agreement Will Give Biosite Automated Platform For BNP Assay
Biosite will leverage Beckman Coulter's U.S. installed base of automated immunoassay analyzers to grow its market share in BNP testing under a long-term development deal between the firms
ACB Cardiac Marker May Receive Same Reimbursement Rate As BNP – Root
A modified albumin point-of-care test for ruling out heart attacks likely will receive similar reimbursement to the $47 rate for B-type natriuretic peptide tests, according to Charles Root, president of consulting firm MCF Compliance